Cancer Immunotherapy: New Approvals and Solid Tumor Breakthroughs

FDA approves iberdomide (Zenbexus) for RRMM, a novel CELMoD active after IMiD failure. Novel approach targeting tumor 'softness' enhances CAR-T in solid tumors. Dual BCMA/GPRC5D CAR-T shows 78% ORR in myeloma. mRNA vaccines (autogene cevumeran) and off-the-shelf CAR-T (vispa-cel) continue to advance. First CAR-T for solid tumor approved in China. CAR T therapy (obecabtagene autoleucel) for relapsed adult B-ALL shows nearly 80% remission vs 55% controls, OS nearly doubled.